News & Updates

Treatment with stereotactic body radiation therapy (SBRT) followed by sorafenib results in better overall (OS) and progression-free survival (PFS), with no increase in adverse events (AEs), compared with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC), as shown in a phase III study presented at the 2023 ASCO GI Cancers Symposium.

Treatment with metformin results in a significant reduction in hepatocellular carcinoma (HCC) incidence following successful antiviral therapy in individuals with diabetes mellitus and chronic hepatitis C (CHC), a recent study has shown.

Isolated hepatitis B core antibody (anti-HBc) positivity appears to increase the risk of liver-related and liver cancer mortality, particularly when accompanied by a high fibrosis score, according to a study of Korean adults.

Treatment with the dual PPAR α/γ agonist saroglitazar helps improve the serum atherogenic lipoprotein profile in patients with nonalcoholic fatty liver disease (NAFLD), regardless of comorbid conditions and statin use, as shown in a study.

Objective response to first-line systemic therapy with lenvatinib or sorafenib independently predicts overall survival (OS) in individuals with unresectable hepatocellular carcinoma (HCC), as shown by the subanalysis of the REFLECT study.

START-FIT, a prospective, single-arm, phase II trial, has found sequential transarterial chemoembolization (TACE) and stereotactic body radiotherapy (SBRT) followed by anti–PD-L1 treatment with avelumab to be a promising strategy for making patients with locally advanced unresectable hepatocellular carcinoma (HCC) amenable to curative treatment.